Cellular therapy as a treatment option for type 1 diabetes (T1D) may benefit from improving current protocols for generating insulin-producing cells (IPCs) from human-induced pluripotent stem cells (hiPSC). The gene discussed is INS; the disease is type 1 diabetes mellitus.